Published On: Wed, Oct 19th, 2016

Current Price Targets For Mirna Therapeutics, Inc. (MIRN)


Recently stock market analysts have updated their consensus ratings on shares of Mirna Therapeutics, Inc. (MIRN).

Most recent broker ratings

09/23/2016 – Mirna Therapeutics, Inc. was downgraded to “neutral” by analysts at H.C. Wainwright. They now have a USD 2 price target on the stock.

09/22/2016 – Mirna Therapeutics, Inc. had its “neutral” rating reiterated by analysts at Citigroup. They now have a USD 2 price target on the stock.

09/21/2016 – Mirna Therapeutics, Inc. was downgraded to “hold” by analysts at Cantor Fitzgerald. They now have a USD 2 price target on the stock.

09/21/2016 – Mirna Therapeutics, Inc. was downgraded to “perform” by analysts at Oppenheimer.

09/21/2016 – Mirna Therapeutics, Inc. had its “market perform” rating reiterated by analysts at Leerink Swann. They now have a USD 1.5 price target on the stock.

Mirna Therapeutics, Inc. has a 50 day moving average of 2.12 and a 200 day moving average of 3.72. The stock’s market capitalization is 35.21M, it has a 52-week low of 1.66 and a 52-week high of 11.01.

The share price of the company (MIRN) was up +1.81% during the last trading session, with a high of 1.73 and the volume of Mirna Therapeutics, Inc. shares traded was 13516.

Mirna Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response. This approach is known as microRNA replacement therapy. Its lead product candidate, MRX34, a mimic of naturally occurring microRNA-34 (miR-34) encapsulated in a liposomal nanoparticle formulation, has demonstrated clinical proof of concept as a single agent in its ongoing Phase I clinical trial. The Company’s RNA molecules function as natural microRNAs when they enter human cells. These RNA molecules, which it calls microRNA mimics, may be used to replace those tumor suppressor microRNAs that are lost, or under expressed, in cancer cells. Its other preclinical product candidates include miR-215, miR-101, miR-16 and let-7.